09:25 AM EDT, 07/23/2024 (MT Newswires) -- AtriCure ( ATRC ) early Tuesday said it has regulatory approval in China to market and sell several models of its AtriClip used to exclude and electrically isolate the left atrial appendage in the heart during cardiac surgery.

The left atrial appendage is a significant source of blood clots in patients with atrial fibrillation. Following approval from the National Medical Products Administration in China, the company now plans to partner with several medical institutions and professionals to provide training and additional support for the new treatment device, according to a statement.

Price: 23.83, Change: +0.01, Percent Change: +0.04